Sanwa Kagaku Kenkyusho Co., Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Nagoya Japan (1953)
Status: No NME R&D (1953)

Organization Overview

First Clinical Trial
2005
NCT00213070
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Sanwa Kagaku Kenkyusho Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Diabetic Nephropathies (Phase 2)

Edema (Phase 2)

Hyperparathyroidism (Phase 3)

Hyperparathyroidism, Secondary (Phase 3)

Hyperuricemia (Phase 2)

Kidney Diseases (Phase 2)

Macular Degeneration (Phase 2)

Macular Edema (Phase 2)

Neoplasm Metastasis (Phase 3)

Nocturia (Phase 2)

Polyuria (Phase 2)

Pruritus (Phase 2)

Retinal Vein Occlusion (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 8